Shares of Merus NV
MRUS,
rallied as much as 10% in the extended session Thursday after the pharma company said the U.S. Food and Drug Administration has granted one of its cancer treatments a breakthrough therapy designation, intended for expedite the development and review of a drug to treat serious illness. The drug, zenocutuzumab, is geared to the treatment of patients with a type of advanced, metastatic pancreatic cancer. Merus plans to provide a clinical update on zenocutuzumab at a “major” medical conference later this year, the company said. The stock ended the regular trading day up 3%.
